Literature DB >> 3100313

Pharmacokinetics of oral glycerol-1-nitrate.

H Laufen, M Leitold, R A Yeates.   

Abstract

The plasma kinetics and urinary excretion of glycerol-1-nitrate (G-1-N), a water soluble metabolite of glycerol trinitrate with anti-anginal potential, have been investigated in healthy human volunteers following oral doses of 10, 20 and 40 mg tablets and 20 mg as drops. In all volunteers G-1-N was rapidly absorbed. The mean concentration-time curves peaked 40 min after administration of tablets at 144 ng/ml (10 mg), 308 ng/ml (20 mg) and 573 ng/ml (40 mg). After the drops the peak of 324 ng/ml occurred at 1 h. The areas under the G-1-N concentration-time curve and the G-1-N peak heights were linear with dose. Tablets and drops can be regarded as bioequivalent with respect to area under the curve and elimination half-life. The bioavailability of the 20 mg tablet relative to the 20 mg drops was 98.6% in terms of area under the curve. The mean apparent half-life of G-1-N elimination from plasma was 2.69 +/- 0.67 h (n = 46). The mean residence time of G-1-N in the body was 4.65 h compared to 0.28 h for glycerol trinitrate after buccal administration. Female volunteers were found to have significantly lower areas under the curve than male volunteers. The difference was probably due to differences in body weight. Renal excretion does not play an important role in the elimination of oral G-1-N from the body. An overall average of 5.42% of the G-1-N dose was excreted in the urine; free drug accounted for 4.02% and conjugated drug for 1.40%.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3100313     DOI: 10.1007/bf00606654

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  43 in total

1.  [Comparative pharmacology of glycerol-1-nitrate and glyceryl trinitrate in various species].

Authors:  M Leitold; H Laufen; R A Yeates
Journal:  Arzneimittelforschung       Date:  1986-05

2.  The absorption and biotransformation of glyceryl trinitrate-1,3-14C by rats.

Authors:  F J DiCarlo; M C Crew; L J Haynes; M D Melgar; R L Gala
Journal:  Biochem Pharmacol       Date:  1968-10       Impact factor: 5.858

3.  A species and developmental comparison of trinitroglycerin metabolism in vitro.

Authors:  R D Short; J C Dacre; C C Lee
Journal:  Biochem Pharmacol       Date:  1977-01-15       Impact factor: 5.858

4.  Plasma concentrations and haemodynamic effects of nitroglycerin during and after intravenous infusion in healthy volunteers.

Authors:  P R Imhof; A Sieber; J Hodler; P Müller; B Ott; P Fankhauser; L C Chu; A Gérardin
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Application of high-performance liquid chromatography with synchronized accumulating radioisotope detector to analysis of glyceryl trinitrate and its metabolites in rat plasma.

Authors:  S Baba; Y Shinohara; H Sano; T Inoue; S Masuda; M Kurono
Journal:  J Chromatogr       Date:  1984-01-13

6.  [Pharmacology of isosorbide dinitrate after transdermal application].

Authors:  A Wildfeuer; H Laufen; M Leitold
Journal:  Arzneimittelforschung       Date:  1985

7.  The metabolic pathway in the degradation of glyceryl trinitrate.

Authors:  P Needleman; D J Blehm; A B Harkey; E M Johnson; S Lang
Journal:  J Pharmacol Exp Ther       Date:  1971-11       Impact factor: 4.030

8.  Metabolism of nitroglycerin in man: influence of phenobarbital.

Authors:  M G Bogaert; M T Rosseel; F M Belpaire
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-07

9.  Application of high-pressure liquid chromatography and thermal energy analyzer to analysis of trinitroglycerin and its metabolites in blood.

Authors:  R J Spanggord; R G Keck
Journal:  J Pharm Sci       Date:  1980-04       Impact factor: 3.534

10.  Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.

Authors:  H Laufen; M Aumann; M Leitold
Journal:  Arzneimittelforschung       Date:  1983
View more
  1 in total

1.  Glyceryl-1-nitrate pharmacokinetics in healthy volunteers.

Authors:  H Laufen; M Leitold
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.